Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure: Short report

To evaluate the use of rosiglitazone and the erythromycin breath test (ERMBT), as probes of CYP2C8 and CYP3A4, respectively, to explain inter-individual variability in paclitaxel exposure